These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. Fine SA; Frohman LA J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585 [TBL] [Abstract][Full Text] [Related]
6. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552 [TBL] [Abstract][Full Text] [Related]
7. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363 [TBL] [Abstract][Full Text] [Related]
8. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. Jonkers N; Sarre S; Ebinger G; Michotte Y J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076 [TBL] [Abstract][Full Text] [Related]
9. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase. Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219 [TBL] [Abstract][Full Text] [Related]
10. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase. Wilke WL Pediatr Res; 1983 Nov; 17(11):924-5. PubMed ID: 6359046 [TBL] [Abstract][Full Text] [Related]
11. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Gilbert JA; Frederick LM; Ames MM Clin Cancer Res; 2000 Nov; 6(11):4365-72. PubMed ID: 11106255 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)]. García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591 [No Abstract] [Full Text] [Related]
13. A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Ogawa A; Kanazawa M; Takayanagi M; Kitani Y; Shintaku H; Kohno Y Brain Dev; 2008 Jan; 30(1):82-5. PubMed ID: 17590551 [TBL] [Abstract][Full Text] [Related]
14. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Admani AK; Verma S; Cordingley GJ; Harris RI Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292 [TBL] [Abstract][Full Text] [Related]
15. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Buck K; Ferger B Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284 [TBL] [Abstract][Full Text] [Related]
16. Pituitary hormone secretion after inhibition of L-aromatic amino acid decarboxylase activity in man. Delitala G; Devilla L; Pende A Acta Endocrinol (Copenh); 1980 Dec; 95(4):438-43. PubMed ID: 7456974 [TBL] [Abstract][Full Text] [Related]
17. L-dopa as substrate for human duodenal catechol-O-methyltransferase and aromatic L-amino acid decarboxylase. Schultz E Biomed Chromatogr; 1990 Nov; 4(6):242-4. PubMed ID: 2289048 [TBL] [Abstract][Full Text] [Related]
18. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study. Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067 [No Abstract] [Full Text] [Related]
19. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration. Lee WY; Lee EA; Jeon MY; Kang HY; Park YG Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase. Waterhouse MJ; Chia YC; Lees GJ Mol Pharmacol; 1979 Jan; 15(1):108-14. PubMed ID: 423884 [No Abstract] [Full Text] [Related] [Next] [New Search]